BetriXa 40 Capsule

Betrixaban
40mg
Square Pharmaceuticals Ltd.
Pack size 10's Pack
Unite Price 65.00 BDT

Indications

BetriXa 40 Capsule is used for: Venous Thromboembolism Prevention

Adult Dose

Venous Thromboembolism Prevention Indicated for prophylaxis of venous thromboembolism (VTE) in adults hospitalized for acute medical illness who are at risk for thromboembolic complications owing to moderate or severe restricted mobility and other risk factors for VTE Initial single dose: 160 mg PO, THEN 80 mg PO qDay Recommended duration of treatment: 35-42 days Hepatic impairment Not recommended; drug was not evaluated in hepatic impairment, because these patients may have intrinsic coagulation abnormalities

Child Dose

Renal Dose

Renal impairment Mild-to-moderate (CrCl >30 mL/min): No dose adjustment needed Severe (CrCl >15 to <30 mL/min): Initial single dose of 80 mg, then 40 mg PO qDay x35-42 days

Administration

Take with food at approximately the same time each day

Contra Indications

Active pathological bleeding Severe hypersensitivity

Precautions

Increases bleeding risk and can cause serious and potentially fatal bleeding; promptly evaluate any signs or symptoms of blood loss; there is no established way to reverse betrixaban’s anticoagulant effect, which can persist for at least 72 hr after the last dose; protamine, vitamin K, and tranexamic acid are not expected to reverse betrixaban anticoagulant activity Risk of paralysis with neuraxial anesthesia Increased bleeding risk with severe renal impairment

Pregnancy-Lactation

Pregnancy No data exist with use in pregnant women, but treatment is likely to increase risk of hemorrhage during pregnancy and delivery Use during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus Animal studies Although betrixaban has not been associated with adverse developmental fetal outcomes in animals, maternal toxicity (ie, hemorrhage) was identified in these studies Lactation Unknown if distributed in human breast milk Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

Interactions

Coadministration with drugs affecting hemostasis increases bleeding risk; examples include aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs

Side Effects

Side effects of Betrixaban : 1-10% Clinically relevant nonmajor bleeding (2.45%) Epistaxis (2%) Hematuria (2%) <1% Bleeding Major bleeding (0.67%) GI bleeding (0.51%) Intracranial hemorrhage (0.05%) Fatal bleeding (0.03%)

Mode of Action

Oral factor Xa (FXa) inhibitor that selectively blocks the active site of FXa and does not require a cofactor (eg, antithrombin III) for activity; inhibits free FXa and prothrombinase activity By directly inhibiting FXa, betrixaban decreases thrombin generation Has no direct effect on platelet aggregation Blood coagulation cascade is dependent upon the activation of factor X to FXa via the intrinsic and extrinsic pathways, which play a central role in the blood coagulation cascade

Note

BetriXa 40 40mg Capsule generic name is Betrixaban. BetriXa 40 40mg Capsule is manufactured by Square Pharmaceuticals Ltd.BetriXa 40 is availble in all over Bangladesh. Mes BD drug index information on BetriXa 40 Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Betrixaban :